Targeting ILCs, their key upstream activating mediators (e.g., IL-23, IL-1β, or IL6), their survival factors (e.g., IL-7), or their effector cytokines (IL-22, IL-17, and IFNγ) hold promise for treating inflammatory diseases such as IBD. Here, IL17A is linked to inflammatory bowel disease.